2019 年第 2 期 第 14 卷

藏药仁青常觉和坐珠达西治疗赤巴性胃炎的效果及对患者肝肾功能的影响

Effects of Tibetan medicine Renqingchangjue and Zuozhudaxi on chronic atrophic gastritis and liver and kidney function

作者：央金卓玛

英文作者：

单位：100029中国藏学研究中心北京藏医院藏药浴科

英文单位：

关键词：赤巴性胃炎；仁青常觉；坐珠达西；肝肾功能

英文关键词：

• 摘要：

• 【摘要】目的    研究藏药仁青常觉和坐珠达西治疗赤巴性胃炎（热性萎缩性胃炎）的效果及对患者肝肾功能的影响。方法    选取2017年1月至2018年1月在中国藏学研究中心北京藏医院确诊赤巴性胃炎的患者165例。完全随机分为仁青常觉组、坐珠达西组和阳性对照组，各55例。坐珠达西组患者给予坐珠达西治疗，仁青常觉组患者给予仁青常觉治疗，阳性对照组患者给予兰索拉唑联合阿莫西林治疗。检测胃动素和胃泌素表达，并统计3组患者临床症状改善时间、治疗有效率，检测患者3组患者血尿素氮水平，检测丙氨酸转氨酶（ALT）和天冬氨酸转氨酶（AST）水平，观察并发症发生情况。结果    治疗后仁青常觉组患者胃动素和胃泌素水平明显低于坐珠达西组和阳性对照组，坐珠达西组治疗后胃动素和胃泌素水平明显低于阳性对照组；仁青常觉组患者临床症状改善时间明显短于坐珠达西组和阳性对照组，坐珠达西组临床病症改善时间明显短于阳性对照组；仁青常觉组治疗总有效率明显高于坐珠达西组、阳性对照组［96.4%（53/55）比81.8%（45/55）、72.7%（40/55）］，坐珠达西组治疗总有效率明显高于阳性对照组，差异均有统计学意义（均P＜0.05）。仁青常觉组治疗后血尿素氮、ALT和AST水平明显低于坐珠达西组和阳性对照组，坐珠达西组组治疗后血尿素氮、ALT和AST水平明显低于阳性对照组，差异均有统计学差异（均P＜0.05）。仁青常觉组并发症发生率明显低于坐珠达西组和阳性对照组［5.5%（3/55）比9.1%（5/55）、20.0%（11/55）］，坐珠达西组患者并发症发生率明显低于阳性对照组，差异均有统计学差异（均P＜0.05）。结论    藏药仁青常觉和坐珠达西对赤巴性胃炎均有一定的治疗效果，能有效控制赤巴性胃炎患者并发症发生情况，且仁青常觉治疗效果更佳。

• 【Abstract】Objective    To observe the effects of Tibetan medicine Renqingchangjue and Zuozhudaxi on chronic atrophic gastritis and liver and kidney function. Methods    From January 2017 to January 2018, 165 patients diagnosed of chronic atrophic gastritis in Beijing Tibetan Hospital, China Tibetology Research Center were randomly divided into Renqingchangjue group, Zuozhudaxi group and positive control group（lansoprazole plus amoxicillin）, with 55 cases in each group. Motilin and gastrin were detected. Clinical symptom improving time and therapeutic efficiency were analyzed. Blood urea nitrogen(BUN), alanine aminotransferase(ALT) and aspartate aminotransferase(AST) were detected. Complications were observed. Results    After treatment, levels of motilin and gastrin in Renqingchangjue group were lower than those in Zuozhudaxi group and positive control group; the levels in Zuozhudaxi group were lower than those in positive control group（P＜0.05）. Clinical symptom improving time in Renqingchangjue group was shorter than that in Zuozhudaxi group and positive control group; clinical symptom improving time in Zuozhudaxi group was shorter than that in positive control group（P＜0.05）. The total effective rate in Renqingchangjue group was higher than that in Zuozhudaxi group and positive control group［96.4%（53/55） vs 81.8%（45/55）, 72.7%（40/55）］; the total effective rate in Zuozhudaxi group was higher than that in positive control group（P＜0.05）. Levels of BUN, ALT and AST in Renqingchangjue group were lower than those in Zuozhudaxi group and positive control group; the levels in Zuozhudaxi group were lower than those in positive control group (P<0.05). The incidence of complications in Renqingchangjue group was lower than that in Zuozhudaxi group and positive control group［5.5%（3/55） vs 9.1%（5/55）, 20.0%（11/55）］; the incidence of complications in Zuozhudaxi group was lower than that in positive control group（P＜0.05）. Conclusion    Tibetan medicine Renqingchangjue shows a better therapeutic effect than Zuozhudaxi in the treatment of chronic atrophic gastritis.